|
WO2021051079A1
|
|
Methods and compositions for assessing and predicting therapeutic response
|
|
WO2020172113A1
|
|
Scar reducing wound closure materials
|
|
WO2020204977A1
|
|
Anti-nmda receptor antibodies and methods of use
|
|
WO2019227039A1
|
|
Compositions comprising antibodies to rabies virus and the uses thereof
|
|
EP3681498A1
|
|
Methods and compositions for the treatment of cancer
|
|
WO2019051198A1
|
|
Prodrug inhibitors of indoleamine 2,3-dioxygenase 1 (ido1)
|
|
WO2018213331A1
|
|
Compositions comprising ligands to rhob protein and the uses thereof
|
|
EP3601558A1
|
|
Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas
|
|
AU2017374043A1
|
|
Immunomodulatory compounds
|
|
WO2018071323A1
|
|
Methods and compositions for assessing and treating emetogenic drug-related nausea
|
|
CA2992145A1
|
|
Methods and compositions for the treatment of immunomodulatory diseases and disorders
|
|
EP2369936A1
|
|
Compositions and methods for the treatment and prevention of lens fibrotic diseases
|
